Nearest Upcoming Biotech Catalysts

Biotech catalysts — PDUFA decisions, AdCom meetings, clinical trial readouts, FDA approvals, and patent expirations — are the events that move small- and mid-cap biotech stocks. This ranking merges every catalyst type into a single list, nearest first, so you can see what is coming across the sector.

Top 100 · updated Jul 2, 2026.

  1. 1Phase 2 Start: Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in CombinatioImmunityBio, Inc. (IBRX)Jul 6, 2026Phase2 Start
  2. 2Phase 2 Start: Evaluating Safety and Efficacy of Ublituximab in Participants With SchizophreniaTG THERAPEUTICS, INC. (TGTX)Jul 6, 2026Phase2 Start
  3. 3Phase 1 Start: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study to Investigate the SBIOGEN INC. (BIIB)Jul 7, 2026Phase1 Start
  4. 4Phase 1 Start: A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINEPFIZER INC (PFE)Jul 9, 2026Phase1 Start
  5. 5Phase 3 Topline: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to SoBRISTOL MYERS SQUIBB CO (BMY)Jul 9, 2026Phase3 Topline
  6. 6Phase 3 Topline: Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic RNasus Pharma Ltd (NSRX)Jul 12, 2026Phase3 Topline
  7. 7Phase 2 Start: A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate theARGENX SE (ARGX)Jul 13, 2026Phase2 Start
  8. 8Patent/Exclusivity Expiry: OPILLPERRIGO Co plc (PRGO)Jul 13, 2026Patent Expiry
  9. 9Phase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. ONovo Nordisk A/S (NVO)Jul 14, 2026Phase3 Topline
  10. 10Phase 3 Topline: A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to DeNovartis AG (NVS)Jul 15, 2026Phase3 Topline
  11. 11Phase 2 Start: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of ALN-CIDEB in Adults With Fibrotic REGENERON PHARMACEUTICALS, INC. (REGN)Jul 15, 2026Phase2 Start
  12. 12Phase 2 Start: An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism ofTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)Jul 15, 2026Phase2 Start
  13. 13Phase 2 Start: Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With XBiotech Inc. (XBIT)Jul 15, 2026Phase2 Start
  14. 14Phase 3 Topline: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy Crinetics Pharmaceuticals, Inc. (CRNX)Jul 16, 2026Phase3 Topline
  15. 15Phase 1 Start: A Phase 1 Study With Expansion of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MMarker Therapeutics, Inc. (MRKR)Jul 16, 2026Phase1 Start
  16. 16Phase 2 Start: A Two Cohort, Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-Center Signal-Finding StuValneva SE (VALN)Jul 17, 2026Phase2 Start
  17. 17Phase 2 Start: A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other BRISTOL MYERS SQUIBB CO (BMY)Jul 17, 2026Phase2 Start
  18. 18Phase 1 Start: An Open-label, Two-part Trial to Assess the Mass-balance Recovery, Metabolite Profile, Metabolite IdAgomAb Therapeutics NV (AGMB)Jul 20, 2026Phase1 Start
  19. 19Phase 2 Start: A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, TolerabilitMerck & Co., Inc. (MRK)Jul 20, 2026Phase2 Start
  20. 20Phase 1 Start: AN INTERVENTIONAL, PHASE 1B, DOUBLE-BLIND, RANDOMIZED, SPONSOR-OPEN, 2-ARM STUDY TO INVESTIGATE THE PFIZER INC (PFE)Jul 22, 2026Phase1 Start
  21. 21Earnings Report: second quarterMolina Healthcare Inc (MOH)Jul 22, 2026Earnings
  22. 22Phase 2 Start: Open-Label, Single-Arm Phase 2 Study Of Nogapendekin Alfa Inbakicept, PD-L1 T-HaNK, And Bevacizumab ImmunityBio, Inc. (IBRX)Jul 22, 2026Phase2 Start
  23. 23Earnings Report: second quarter 2026Quest Diagnostics Incorporated (DGX)Jul 23, 2026Earnings
  24. 24Phase 2 Start: A Phase 1/2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular HypertensiREGENERON PHARMACEUTICALS, INC. (REGN)Jul 23, 2026Phase2 Start
  25. 25Phase 3 Topline: A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANTBioNTech SE (BNTX)Jul 23, 2026Phase3 Topline
  26. 26Phase 1 Start: A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, TolerabiASTRAZENECA PLC (AZN)Jul 23, 2026Phase1 Start
  27. 27Phase 2 Start: A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and SaASTRAZENECA PLC (AZN)Jul 28, 2026Phase2 Start
  28. 28Phase 1 Start: A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)ENANTA PHARMACEUTICALS INC (ENTA)Jul 28, 2026Phase1 Start
  29. 29Phase 2 Start: Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor FATE THERAPEUTICS INC (FATE)Jul 29, 2026Phase2 Start
  30. 30PDUFA Date: ons-5010Outlook Therapeutics, Inc. (OTLK)Jul 29, 2026PDUFA
  31. 31Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the EfficaTG THERAPEUTICS, INC. (TGTX)Jul 30, 2026Phase3 Topline
  32. 32Phase 3 Topline: A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton SyndrQuoin Pharmaceuticals, Ltd. (QNRX)Jul 30, 2026Phase3 Topline
  33. 33Phase 2 Start: Open-label, Phase I/II Study to Evaluate Safety and Efficacy of Asciminib With Chemotherapy FollowedNovartis AG (NVS)Jul 30, 2026Phase2 Start
  34. 34Earnings Report: second quarter 2026AGIOS PHARMACEUTICALS, INC. (AGIO)Jul 30, 2026Earnings
  35. 35Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting ReModerna, Inc. (MRNA)Jul 30, 2026Phase3 Topline
  36. 36Phase 3 Topline: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERABioNTech SE (BNTX)Jul 31, 2026Phase3 Topline
  37. 37Phase 2 Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, SafeAMGEN INC (AMGN)Jul 31, 2026Phase2 Start
  38. 38Phase 2 Start: NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With DinutuximabUNITED THERAPEUTICS Corp (UTHR)Jul 31, 2026Phase2 Start
  39. 39Phase 3 Topline: A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162b2 (LP.8.1BioNTech SE (BNTX)Jul 31, 2026Phase3 Topline
  40. 40Phase 3 Topline: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-ENANTA PHARMACEUTICALS INC (ENTA)Jul 31, 2026Phase3 Topline
  41. 41Phase 1 Start: Prospective, Multi-Center, Open-Label, Non-Randomized, Multi-Arm Study to Evaluate the Safety, EfficSpyGlass Pharma Inc. (SGP)Jul 31, 2026Phase1 Start
  42. 42Phase 3 Topline: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of PaSol-Gel Technologies Ltd. (SLGL)Aug 1, 2026Phase3 Topline
  43. 43Phase 2 Readout: elpis iiLongeveron Inc. (LGVN)Aug 1, 2026Phase2 Topline
  44. 44Phase 3 Topline: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and SaIONIS PHARMACEUTICALS INC (IONS)Aug 1, 2026Phase3 Topline
  45. 45Phase 3 Topline: A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 TeAbbVie Inc. (ABBV)Aug 1, 2026Phase3 Topline
  46. 46Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy BIOMARIN PHARMACEUTICAL INC (BMRN)Aug 1, 2026Phase3 Topline
  47. 47Phase 2 Readout: laromestrocelLongeveron Inc. (LGVN)Aug 1, 2026Phase2 Topline
  48. 48Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety ofPharvaris N.V. (PHVS)Aug 1, 2026Phase3 Topline
  49. 49Phase 3 Topline: Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a MultiCrinetics Pharmaceuticals, Inc. (CRNX)Aug 1, 2026Phase3 Topline
  50. 50Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the EfLEXICON PHARMACEUTICALS, INC. (LXRX)Aug 1, 2026Phase3 Topline
  51. 51Phase 3 Topline: A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult PWest Pharmaceutical Services Inc. (WST)Aug 1, 2026Phase3 Topline
  52. 52Phase 2 Start: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the EScholar Rock Holding Corp (SRRK)Aug 1, 2026Phase2 Start
  53. 53Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Serum Virus Neutralizing Antibody Invivyd, Inc. (IVVD)Aug 1, 2026Phase3 Topline
  54. 54Phase 2 Start: A Phase 1/2 Open-Label Intrathecal Administration of TSHA-105 to Determine the Safety and Efficacy iGH Research PLC (GHRS)Aug 1, 2026Phase2 Start
  55. 55Phase 3 Topline: A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ofInvivyd, Inc. (IVVD)Aug 1, 2026Phase3 Topline
  56. 56Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly VadaAkebia Therapeutics, Inc. (AKBA)Aug 1, 2026Phase3 Topline
  57. 57Phase 3 Topline: A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese ParNovo Nordisk A/S (NVO)Aug 3, 2026Phase3 Topline
  58. 58Earnings Report: second-quarter 2026Viatris Inc (VTRS)Aug 6, 2026Earnings
  59. 59Phase 2 Start: A Phase 2 Study of RP2 With Tivozanib in Patients With Metastatic Renal Carcinoma After Progression Replimune Group, Inc. (REPL)Aug 11, 2026Phase2 Start
  60. 60Phase 3 Topline: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With AtezolizJazz Pharmaceuticals plc (JAZZ)Aug 13, 2026Phase3 Topline
  61. 61Phase 2 Start: A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for TreatmentAcurx Pharmaceuticals, Inc. (ACXP)Aug 19, 2026Phase2 Start
  62. 62Phase 3 Topline: A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive ASTRAZENECA PLC (AZN)Aug 19, 2026Phase3 Topline
  63. 63PDUFA Date: deramiocelCAPRICOR THERAPEUTICS, INC. (CAPR)Aug 22, 2026PDUFA
  64. 64PDUFA Date: dtx401 aav gene therapyUltragenyx Pharmaceutical Inc. (RARE)Aug 23, 2026PDUFA
  65. 65Phase 2 Start: A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 DiabetesNovo Nordisk A/S (NVO)Aug 27, 2026Phase2 Start
  66. 66Phase 3 Topline: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line ASTRAZENECA PLC (AZN)Aug 27, 2026Phase3 Topline
  67. 67Phase 2 Start: A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in REGENERON PHARMACEUTICALS, INC. (REGN)Aug 31, 2026Phase2 Start
  68. 68Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the EffSanofi (SNY)Aug 31, 2026Phase3 Topline
  69. 69Phase 3 Topline: Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa PatENANTA PHARMACEUTICALS INC (ENTA)Aug 31, 2026Phase3 Topline
  70. 70Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial ChemoeASTRAZENECA PLC (AZN)Aug 31, 2026Phase3 Topline
  71. 71Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label SafetyZenas BioPharma, Inc. (ZBIO)Aug 31, 2026Phase3 Topline
  72. 72Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel ForUroGen Pharma Ltd. (URGN)Sep 1, 2026Phase3 Topline
  73. 73Phase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double BliUNITED THERAPEUTICS Corp (UTHR)Sep 1, 2026Phase3 Topline
  74. 74Phase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and PharmELI LILLY & Co (LLY)Sep 1, 2026Phase3 Topline
  75. 75Phase 1 Start: Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients WiINTEGRATED BIOPHARMA INC (INBP)Sep 1, 2026Phase1 Start
  76. 76Phase 1 Start: A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in PartContext Therapeutics Inc. (CNTX)Sep 1, 2026Phase1 Start
  77. 77Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel FollowingRenovoRx, Inc. (RNXT)Sep 1, 2026Phase3 Topline
  78. 78Phase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety anTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)Sep 1, 2026Phase2 Start
  79. 79Phase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of AficaCYTOKINETICS INC (CYTK)Sep 1, 2026Phase3 Topline
  80. 80Phase 2 Start: Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy and Safety of VXBiotech Inc. (XBIT)Sep 1, 2026Phase2 Start
  81. 81Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity Arcturus Therapeutics Holdings Inc. (ARCT)Sep 1, 2026Phase2 Start
  82. 82Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the EffVeradermics Incorporated (MANE)Sep 1, 2026Phase3 Topline
  83. 83Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in ARROWHEAD PHARMACEUTICALS, INC. (ARWR)Sep 1, 2026Phase3 Topline
  84. 84Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran inARROWHEAD PHARMACEUTICALS, INC. (ARWR)Sep 1, 2026Phase3 Topline
  85. 85Phase 2 Start: Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized ControlledGH Research PLC (GHRS)Sep 1, 2026Phase2 Start
  86. 86Phase 3 Topline: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess CoCYBIN INC. (HELP)Sep 1, 2026Phase3 Topline
  87. 87Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain Alkermes plc. (ALKS)Sep 1, 2026Phase3 Topline
  88. 88Phase 1 Start: An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone Dare Bioscience, Inc. (DARE)Sep 1, 2026Phase1 Start
  89. 89Phase 2 Readout: rademikibartConnect Biopharma Holdings Ltd (CNTB)Sep 1, 2026Phase2 Topline
  90. 90Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and EffiARDELYX, INC. (ARDX)Sep 1, 2026Phase3 Topline
  91. 91Phase 1 Start: A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety andZai Lab Ltd (ZLAB)Sep 3, 2026Phase1 Start
  92. 92Phase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With ChemotheraASTRAZENECA PLC (AZN)Sep 17, 2026Phase3 Topline
  93. 93Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of FluticasoneTeva Pharmaceutical Industries Limited (TEVA)Sep 19, 2026Phase3 Topline
  94. 94Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide MonotPFIZER INC (PFE)Sep 19, 2026Phase3 Topline
  95. 95PDUFA Date: zilganersenIONIS PHARMACEUTICALS INC (IONS)Sep 22, 2026PDUFA
  96. 96Phase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 VNovartis AG (NVS)Sep 23, 2026Phase3 Topline
  97. 97Phase 3 Topline: A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an InvestigSanofi (SNY)Sep 23, 2026Phase3 Topline
  98. 98Phase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in CombinatiASTRAZENECA PLC (AZN)Sep 24, 2026Phase3 Topline
  99. 99PDUFA Date: relutriginePraxis Precision Medicines, Inc. (PRAX)Sep 27, 2026PDUFA
  100. 100Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIOcugen, Inc. (OCGN)Sep 28, 2026Phase3 Topline

Ranked by soonest date. Only dates confirmed in a primary source (SEC filing, FDA source, or company disclosure) are shown; speculative far-future dates are excluded.

Frequently asked questions

What counts as a biotech catalyst?

A catalyst is a scheduled or expected event that can materially move a stock — most commonly PDUFA dates, AdCom meetings, Phase 2/3 trial readouts, FDA approvals, and patent expirations.

How are catalyst dates verified?

BioSniper only shows a date when it appears in a primary source (SEC filing, FDA source, or company disclosure); speculative far-future dates are excluded.

How often is this ranking updated?

The catalyst calendar is refreshed hourly.